GlassScriptPhysician profile
Jeffrey J Calhoun
NPI 1700878006
$2,693.13
in general payments reported to CMS, 2019-2025
15 companies · $651 in 2025
The $651 reported for 2025 was more than what 89% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $158 · 2021: $291 · 2022: $172 · 2023: $419 · 2024: $574 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $621.82 | 2023-2025 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $594.44 | 2019-2021 | |
| Coopervision INC. | $353.87 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $268.51 | 2020-2024 | |
| Alcon Vision LLC | $192.33 | 2023-2025 | Precision7, Total30, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $124.99 | 2025 | Xdemvy |
| Harrow Eye, LLC | $121.03 | 2025 | Vevye |
| Horizon Therapeutics Plc | $114.90 | 2022 | |
| Lkc Technologies, INC. | $95.51 | 2023 | |
| Sight Sciences, INC. | $81.42 | 2019-2024 | Tearcare System |
| Topcon Healthcare, INC. | $57.19 | 2022 | |
| Maculogix, INC. | $20.83 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abb Con-Cise Optical Group LLC | $13.74 | 2019 | |
| Optovue, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.